Literature DB >> 12431468

Late locoregional recurrence in rectal carcinoma.

S Merkel1, T Meyer, J Göhl, W Hohenberger.   

Abstract

AIMS: Locoregional recurrence in rectal carcinoma usually occurs within the first five years of treatment. In recent years we have increasingly diagnosed patients with late locoregional recurrence more than 5 years after primary treatment.
METHODS: The data of 978 patients with invasive stage I-III rectal carcinoma who underwent curative resection (R0) between 1978 and 1990 were analysed retrospectively. The median follow-up time was 10 years.
RESULTS: The earliest locoregional recurrence was observed at 2 months, the latest at 148 months (extramural locoregional recurrence) after primary treatment. Within 1, 2 and 5 years 34, 64 and 91 per cent of all locoregional recurrences had been diagnosed. The 2-, 5- and 10-year locoregional recurrence rates of all patients increased from 11.3 to 16.7 to 18.8 per cent. The time lapse to diagnosis of locoregional recurrence was significantly influenced by the pN category (pN0: later), grading (low grade: later) and tumour cell dissemination (present: earlier). Locoregional recurrence was also diagnosed significantly earlier in patients undergoing regular follow-up. The curative reoperation rate was 22 per cent (n=37), being higher in patients with intramural locoregional recurrence (49 per cent), after primary anterior resection (32 per cent) and in the absence of distant metastases (29 per cent).
CONCLUSION: Long-term follow-up beyond five years demonstrates increasing numbers of late locoregional recurrences.

Entities:  

Mesh:

Year:  2002        PMID: 12431468     DOI: 10.1053/ejso.2002.1305

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  10 in total

1.  Late-occurring liver metastases in colorectal cancer.

Authors:  Francisco Rodríguez-Moranta; Antoni Castells; Rosa Miquel; Virginia Piñol; Joan Maurel; Josep Fuster; Antonio M Lacy; Josep M Piqué
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

2.  Quality management in rectal carcinoma: what is feasible?

Authors:  Susanne Merkel; Daniela Klossek; Jonas Göhl; Thomas Papadopoulos; Werner Hohenberger; Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2009-06-02       Impact factor: 2.571

Review 3.  [Neoadjuvant radiochemotherapy for rectal cancer].

Authors:  W Hohenberger; G Lahmer; R Fietkau; R S Croner; S Merkel; J Göhl; R Sauer
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

4.  [Open surgery of the rectum].

Authors:  W Hohenberger
Journal:  Chirurg       Date:  2007-08       Impact factor: 0.955

5.  Survival analysis in rectal carcinoma after neoadjuvant chemoradiation: various methods with different results.

Authors:  Susanne Merkel; Klaus Weber; Jonas Göhl; Abbas Agaimy; Rainer Fietkau; Werner Hohenberger; Robert Grützmann; Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2017-07-20       Impact factor: 2.571

6.  [Present treatment strategies for rectal carcinoma].

Authors:  T Liersch; C Langer; B M Ghadimi; H Becker
Journal:  Chirurg       Date:  2005-03       Impact factor: 0.955

7.  Regional lymph node metastasis and locoregional recurrence of rectal carcinoma in the era of TME [corrected] surgery. Implications for treatment decisions.

Authors:  Paul Hermanek; Susanne Merkel; Rainer Fietkau; Claus Rödel; Werner Hohenberger
Journal:  Int J Colorectal Dis       Date:  2009-12-10       Impact factor: 2.571

8.  [Problems in the treatment of upper rectal carcinoma].

Authors:  T Junginger; P Hermanek
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

9.  Survival after surgical treatment of cancer of the rectum.

Authors:  W Hohenberger; B Bittorf; T Papadopoulos; S Merkel
Journal:  Langenbecks Arch Surg       Date:  2004-08-12       Impact factor: 3.445

Review 10.  [Rational staging and follow-up of colorectal cancer : Do guidelines provide further help?]

Authors:  M S Juchems; J Wessling
Journal:  Radiologe       Date:  2019-09       Impact factor: 0.635

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.